LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.: APPLICATION NO.: 88066-8099 APPLICANT: 10/798,161 Carrara et al. GROUP: March 10, 2004 1614

			U.S. PATENT DOCUMENTS									
	*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DAYE IF APPROPRIATE				
	K6	1	4,082,881	4-4-78	Chen et al.	424	241					
	1	2	4,315,925	2-16-82	Hussaiin et al.	424	239					
		3	4,383,993	5-17-83	Hussaiin et al.	424	239					
		4	4,390,532	6-28-83	Stuttgen et al.	424	240					
		5	4,537,776	8-7-85	Соорет	514	424					
		6	4,863,970	9-5-89	Patel et al.	514	784					
		7	5,071,657	12-10-91	Oloff	424	486					
		8	5,128,138	7-7-92	Blank	424	449					
		9	5,178,879	1-12-93	Adekunle et al.	424	484					
ı		10	5,232,703	8-3-93	Blank	424	449					
		11	5,238,933	8-24-93	Catz	514	236.2					
		12	5,371,005	12-6-94	Fujishiro et al.	435	190					
		13	5,602,017	2-11-97	Fujishiro et al.	435	190					
		14	5,629,021	5-13-97	Wright	424	489					
		15	5,660,839	8-26-97	Allec et al.	424	401					
•		16	5,665,560	9-9-97	Fujishiro et al.	435	11					
		17	5,716,638	2-10-98	Touitou	424	450					
		18	5,731,303	3-24-98	Hsien	514	183					
		19	5,798,242	8-25-98	Fujishiro et al.	435	190					
		20	5,831,035	11-3-98	Timms	530	389.1					
		21	5,855,920	1-5-99	Chein	424	568					
		22	5,891,462	4-6-99	Сагтага	424	449					
		23	5,904,931	5-18-99	Lipp	424	449					
٠		24	5,968,919	10-19-99	Samour	514	177					
	ł	25	6,008,192	12-28-99	Al Razzak et al.	514	11					
	KO	26	6,060,077	5-9-00	Meignant	424	434					

	- \								
. 1	H-10	27	6,096,733	8-1-00	Lubkin	514	182		
	EMPE	28	6,153,216	11-28-00	Cordes	424	449		
RAS		29	6,180,803	1-30-2001	Piasco et al.	552	150		
		30	6,214,374	4-10-01	Schmirier et al.	424	449		
•		31	6,284,234	9-4-01	Niemiec	424	78.07		
		32	6,309,843	10-30-01	Timms	435	7.1		
		33	6,319,913	11-20-01	Mak et al.	514	179		
		34	6,440,454	8-27-02	Santoro et al.	424	449		
	·	35	6,444,234	9-3-02	Kirby et al.	424	725		
		36	6,476,012	11-5-02	Hochberg	514	182		
		37	6,497,897	12-24-02	Hidaka et al.	424	449		
	K6	38	6,503,894	1-7-03	Dudley	514	178		
				U.S. PUBL	ISHED PATENT APPLICATIONS				
	KG	39	2001/0023261	9-20-01	Ryoo	514	772		
	1	40 2001/0033870		10-25-01	Luo	424	688		
		41	2002/0183296	12-5-02	Dudley et al.	514	177		- 4
		42	2003/0181430	9-25-03	Gray et al.	514	170		
		43	2003/0022877	1-30-03	Dudley	514	177		
		44	2003/0050292	3-13-03	Dudley	514	177		
		45	2003/0139384	7-24-03	Dudley	514	177		
		46	2003/0232072	12-18-03	Dudley et al.	424	449		
	K6	47	2004/0002482	1-1-04	Dudley et al.	514	169		
				FORE	IGN PATENT DOCUMENTS				
			DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI.	MOTTA
	K6	48	FR 2518879	12-30-81	France (with abstract)	,		х	
	1	49	EP 0250125 B1	9-18-91	ЕР				
Ì		50	EP 0325613 B1	9-8-93	EP				
Ì		51	EP 0409383 B1	4-6-94	ЕР				
		52	EP 0435200 B1	7-12-95	EP				
)	53	EP 785211 A1	7-23-97	ЕР				
	K-6	54	EP 785212 A1	7-23-97	ЕР				
•		•			-				•

SS EP 0491803 B1 7-20-99 EP	1. (I		· · · · · · · · · · · · · · · · · · ·	 			
S7 EP 0804926 B1 10-27-99 EP	K6	55	EP 0491803 B1	7-20-99	EP			_	
S8		56	FR 2776191	9-24-99	France (with abstract)			х	
S9 EP 0719538 B1 11-8-00 EP		57	EP 0804926 B1	10-27-99	EP			_	
60 EP 0814776 B1 7-4-01 EP (with abstract) X 61 EP 0643963 B1 11-14-01 EP 62 EP 0868187 B1 12-5-01 EP 63 EP 0859793 B1 2-13-02 EP 64 EP 1089722 B1 5-22-02 EP 65 EP 0802782 B1 2-5-03 EP 67FOREIGN PUBLISHED PATENT APPLICATIONS 66 WO 92/08730 5-29-92 Laboratoire Theramax SAM Assignee 67 WO 94/06437 3-31-94 Laboratoire Theramax SAM Assignee 68 JP 09176049 7-8-97 Suzuki et al. (with abstract) X 69 WO 97/03676 2-6-97 Cabo et al. (with abstract) X 70 WO 97/34607 9-27-97 Ludwig 71 WO 98/37879 9-3-98 Hsieh 72 WO 99/24041 5-20 Cellegy Pharmaceuticals, Inc. 73 WO 99/24041 5-20 Cellegy Pharmaceuticals, Inc. 74 WO 99/20257 4-29-01 Beier et al. 75 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) *EXAMINER LAMA— DATE CONSIDERED *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not		58	EP 0655900 B1	3-15-00	EP .				
61 EP 0643963 B1 11-14-01 EP 62 EP 0868187 B1 12-5-01 EP 63 EP 0859793 B1 2-13-02 EP 64 EP 1089722 B1 5-22-02 EP 5760REICH PUBLISHED PATENT APPLICATIONS 65 EP 0802782 B1 2-5-03 EP 67 WO 94/06437 3-31-94 Laboratoire Theramax SAM Assignee 68 JP 09176049 7-8-97 Suzuki et al. (with abstract) X 69 WO 97/03676 2-6-97 Cabo et al. (with abstract) X 70 WO 97/34607 9-27-97 Ludwig 71 WO 98/37879 9-3-98 Hsieh 72 WO 99/24041 5-20 Cellegy Pharmaceuticals, Inc. 73 WO 99/24041 5-20 Cellegy Pharmaceuticals, Inc. 74 WO 99/20257 4-29-01 Beier et al. 67 WO 99/20257 4-29-01 Beier et al. 68 JP 09176049 Therefore considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not		59	EP 0719538 B1	11-8-00	EP				_
62 EP 0868187 B1 12-5-01 EP 63 EP 0859793 B1 2-13-02 EP 64 EP 1089722 B1 5-22-02 EP V6 65 EP 0802782 B1 2-5-03 EP 67FOREIGN FUBLISHED PATENT APPLICATIONS 66 WO 92/08730 5-29-92 Laboratoire Theramax SAM Assignee 67 WO 94/06437 3-31-94 Laboratoire Theramax SAM Assignee 68 JP 09176049 7-8-97 Suzuki et al. (with abstract) X 69 WO 97/03676 2-6-97 Cabo et al. (with abstract) X 70 WO 97/34607 9-27-97 Ludwig 71 WO 98/37879 9-3-98 Hsieh 72 WO 99/24041 5-20 Cellegy Pharmaceuticals, Inc. 73 WO 99/48477 9-30-99 Laboratoire Theramax SAM Assignee (with abstract) 74 WO 99/20257 4-29-01 Beier et al. CHECK TO WO 99/20257 4-29-01 Beier et al. EXAMINER W W W DATE REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) *EXAMINER W W DATE CONSIDERED *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not		60	EP 0814776 B1	7-4-01	EP (with abstract)			х	
63 EP 0859793 B1 2-13-02 EP 64 EP 1089722 B1 5-22-02 EP 75 FOREIGN PUBLISHED PATENT APPLICATIONS 84 66 WO 92/08730 5-29-92 Laboratoire Theramax SAM Assignee 67 WO 94/06437 3-31-94 Laboratoire Theramax SAM Assignee 68 JP 09176049 7-8-97 Suzuki et al. (with abstract) 70 WO 97/03676 2-6-97 Cabo et al. (with abstract) 71 WO 98/37879 9-3-98 Hsieh 72 WO 99/24041 5-20 Cellegy Pharmaceuticals, Inc. 73 WO 99/48477 9-30-99 Laboratoire Theramax SAM Assignee (with abstract) 74 WO 99/20257 4-29-01 Beier et al. 84 WO 99/20257 4-29-01 Beier et al. 85 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) 86 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) 87 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) 88 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) 89 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) 80 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) 80 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) 80 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) 80 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) 81 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) 82 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) 83 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) 84 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) 85 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) 86 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) 87 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract)		61	EP 0643963 B1	11-14-01	ЕР				4
63 EP 0859793 B1 2-13-02 EP		62	EP 0868187 B1 12-5-01		EP				
### Action of the process of the pro		63	EP 0859793 B1	2-13-02	ЕР				
66 WO 92/08730 5-29-92 Laboratoire Theramax SAM Assignee 67 WO 94/06437 3-31-94 Laboratoire Theramax SAM Assignee 68 JP 09176049 7-8-97 Suzuki et al. (with abstract) 70 WO 97/03676 2-6-97 Cabo et al. (with abstract) 71 WO 98/37879 9-3-98 Hsieh 72 WO 99/24041 5-20 Cellegy Pharmaceuticals, Inc. 73 WO 99/48477 9-30-99 Laboratoire Theramax SAM Assignee (with abstract) 74 WO 99/20257 4-29-01 Beier et al. 15 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) *EXAMINER** DATE CONSIDERED *EXAMINER** DATE CONSIDERED *EXAMINER** DATE CONSIDERED *EXAMINER** DATE CONSIDERED *EXAMINER** *EXAMINER** DATE CONSIDERED *EXAMINER** *EXAMINER** DATE CONSIDERED *EXAMINER** *EXAMINER** *EXAMINER** DATE CONSIDERED *EXAMINER** *EXAMINER** *EXAMINER** *EXAMINER** *EXAMINER** *EXAMINER** *Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not		64	EP 1089722 B1	5-22-02	EP				
1	. K6	65	EP 0802782 B1	2-5-03	ЕР				
67 WO 94/06437 3-31-94 Laboratoire Theramax SAM Assignee X				67FOREIGN P	UBLISHED PATENT APPLICATIONS				
68 JP 09176049 7-8-97 Suzuki et al. (with abstract) X 69 WC 97/03676 2-6-97 Cabo et al. (with abstract) X 70 WO 97/34607 9-27-97 Ludwig	KC	66	WO 92/08730	5-29-92	Laboratoire Theramax SAM Assignee				
69 WO 97/03676	1	67	WO 94/06437	3-31-94	Laboratoire Theramax SAM Assignee				
70 WO 97/34607 9-27-97 Ludwig 71 WO 98/37879 9-3-98 Hsieh 72 WO 99/24041 5-20 Cellegy Pharmaceuticals, Inc. 73 WO 99/48477 9-30-99 Laboratoire Thermax SAM Assignee (with abstract) 74 WO 99/20257 4-29-01 Beier et al. 75 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) *EXAMINER** DATE CONSIDERED W6605** *EXAMINER** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not		68	JP 09176049	7-8-97	Suzuki et al. (with abstract)			x	
71 WO 98/37879 9-3-98 Hsieh 72 WO 99/24041 5-20 Cellegy Pharmaceuticals, Inc. 73 WO 99/48477 9-30-99 Laboratoire Thermax SAM Assignee (with abstract) 74 WO 99/20257 4-29-01 Beier et al. 75 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) *EXAMINER** DATE CONSIDERED *EXAMINER** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not		69	WO 97/03676	. 2-6-97	Cabo et al. (with abstract)			х	
72 WO 99/24041 5-20 Cellegy Pharmaceuticals, Inc. 73 WO 99/48477 9-30-99 Laboratoire Thermax SAM Assignee (with abstract) 74 WO 99/20257 4-29-01 Beier et al. 75 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) EXAMINER L. DATE CONSIDERED *EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not		70	WO 97/34607	9-27-97	Ludwig				
73 WO 99/48477 9-30-99 Laboratoire Thermax SAM Assignee (with abstract) 74 WO 99/20257 4-29-01 Beier et al. 75 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) EXAMINER LAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not		71	WO 98/37879	9-3-98	Hsieh				
abstract) 74 WO 99/20257 4-29-01 Beier et al. 75 WO 02/22132 2-21-02 Laboratoire Theramax SAM Assignee (with abstract) OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) EXAMINER LAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not		72	WO 99/24041	5-20	Cellegy Pharmaceuticals, Inc.				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) EXAMINER LAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not		73	WO 99/48477	9-30-99				X	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) EXAMINER DATE CONSIDERED *EXAMINE R: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not		74	WO 99/20257	4-29-01	Beier et al.				
*EXAMINE R: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not	16	75	WO 02/22132	2-21-02				х	
*EXAMINE R: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
*EXAMINE R: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not						•			
*EXAMINE R: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not		<u> </u>	EXAMINER /	AM/_	DATE CONSIDERED 12 16	COT			
in conformance and not considered. Include copy of this form with next communication to applicant.	*EVAL	INIE P	Initial if reference consider	rad wheeher	not citation is in conformance with MDED 600.	Draw line th	rough citatio	on if-	ot
	EAAIV.	MAE K	in conformance and no	ot considered.	Include copy of this form with next communication	n to applica	nt.	J. 11 11	<u> </u>

					ATTY. DOCKET NO.:		APPLICATION	NO.:			
				88066-8099	88066-8099						
				APPLICANT:		To Be Ass					
	LIST	OF REFERENCES CITE		Carrara et al.	Carrara et al						
		(Use several sheets if	necessary)	FILING DATE:							
				Herewith		To Be Ass	imad				
							10 DC ASS	Ruca			
			U.S.	. PATENT	DOCUMENTS						
*EXAMINE INITIAL	ER	DOCUMENT NUMBER	DATE .		NAME	CLASS	SUBCLASS	FILING APPRO	DATE IF		
KG	AA	4,952,560	8/28/90	Kigasawa	a et al.	514	2				
KE	AB	5,580,574	12/3/96	Behl et al.		424	449				
	1							1			
		-	1								
			FORE	EIGN PATE	NT DOCUMENTS		<u>.</u>	<u> </u>			
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSI	NO		
KG	S AC	0 672 422 A1	3/14/94	EPO			 				
	AD	0 249 397	12/16/87	ЕРО	,						
	AE	0 811 381 A1	12/10/97	EPO							
Ko	AF	WO 99/24041	5/20/99	PCT							
	-	OTHER RI	EFERENCES (Including A	uthor, Title, Date, Pertinent Page	s, Etc.)					
			·	<u>_</u>	<u> </u>						
					·		•				
							•		-		
		<u> </u>									
	. k	EXAMINER			DATE CONSIDERED	6/05		٠,,.			
*EX	KAMINER	: Initial if reference consider	ered, whether or	not citation	is in conformance with MPEP	609; Draw line	hrough cita	tion if	not		
					v of this form with next commun						